Makary: We Have No Plans to Take Action on Changing Access to Abortion Pill Mifepristone

VITALI And I want ░░░░░░░░ also ask you about ░░░░░░░░ that the Secretary of ░░░░░░░░ and Human Services asked ░░░░░░░░ to review I think ░░░░░░░░ was last month looking ░░░░░░░░ the latest data on ░░░░░░░░ more commonly known as ░░░░░░░░ abortion pill Is that ░░░░░░░░ still ongoing Has it ░░░░░░░░ What are you looking ░░░░░░░░ here And why is ░░░░░░░░ being reviewed in the ░░░░░░░░ place given the fact ░░░░░░░░ there aren t safety ░░░░░░░░ about this drug MAKARY ░░░░░░░░ So as a part ░░░░░░░░ a regulation called the ░░░░░░░░ the risk evaluation and ░░░░░░░░ strategy in prior administrations ░░░░░░░░ was a commitment to ░░░░░░░░ review data on Mifepristone ░░░░░░░░ we re doing that ░░░░░░░░ re abiding by that ░░░░░░░░ That means we look ░░░░░░░░ self reported data in ░░░░░░░░ Adverse Event Reporting Database ░░░░░░░░ means that when studies ░░░░░░░░ that there s a ░░░░░░░░ signal in a large ░░░░░░░░ database we have to ░░░░░░░░ attention to that For ░░░░░░░░ there could be a ░░░░░░░░ drug that could have ░░░░░░░░ drug drug interaction with ░░░░░░░░ So we can t ░░░░░░░░ a blind eye to ░░░░░░░░ s happening with safety ░░░░░░░░ with that drug or ░░░░░░░░ drug so that that ░░░░░░░░ is ongoing VITALI But ░░░░░░░░ it still true for ░░░░░░░░ that you have no ░░░░░░░░ to take action on ░░░░░░░░ access to that drug ░░░░░░░░ That is true VITALI ░░░░░░░░